Popular terms

Autologous topics
Autologous
Stem Cells
Differentiation
Fibroblast
Cell Therapy
Transplant
Cell Differentiation
Tissue Engineering
Myeloid Leukemia
Gene Expression
Acute Myeloid Leukemia
Complication
Umbilical Cord
Premature Birth
Premature Infant

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Autologous patents



      

This page is updated frequently with new Autologous-related patent applications.




Date/App# patent app List of recent Autologous-related patents
07/21/16
20160206696 
 Method of repairing age and disease immune dysfunction and cellular senescence with lymphoid stem cells and then re-applying those for therapeutic use patent thumbnailnew patent Method of repairing age and disease immune dysfunction and cellular senescence with lymphoid stem cells and then re-applying those for therapeutic use
This invention relates to methods for treatment of diseases of ageing including immunosenescence, immune dysfunction, inflammation and impairment of early lymphoid lineage differentiation. The invention more specifically relates to the use of granulocyte colony stimulating factors to assist in stem cell mobilization, optionally in combination with the application of a method of delivering precise magnetic field patterns which agree with the body's own natural magnetic field patterns, and further in combination with re-infusion of previously collected autologous cells and/or plasma, optionally including allogeneic (healthy donor) cells and blood plasma..
Advanced Neuroregenerative Therapies, Llc


07/21/16
20160206689 
 Autologous hiv-1 proteins for the treatment of latent hiv-1 infection patent thumbnailnew patent Autologous hiv-1 proteins for the treatment of latent hiv-1 infection
A method of reducing a latent hiv-specific memory-cd4+ t cell pool in a subject includes the steps of: preparing at least one hiv-1 protein coding sequence from a sample obtained from the subject, wherein the sample includes hiv-1 rna; introducing the at least one hiv-1 protein coding sequence into at least one expression construct using yeast homologous recombination; transfecting a cell with the at least one expression construct, wherein the hiv-1 protein is secreted by the cell and administering a therapeutically effective amount of the secreted hiv-1 protein and a pharmaceutically acceptable carrier to the subject, wherein the secreted hiv-1 protein stimulates latent hiv-specific memory-cd4+ t cells to induce latent hiv-1 replication resulting in hiv-specific memory-cd4+ t cell death in the subject.. .
Case Western Reserve University


07/21/16
20160206551 
 Methods for the repair and rejuvenation of tissues using platelet-rich plasma compositions patent thumbnailnew patent Methods for the repair and rejuvenation of tissues using platelet-rich plasma compositions
This application relates to cosmetic methods for improving skin conditions. The methods generally include the administration of platelet-rich plasma and cultured autologous cells to a subject after a micro-needling procedure has been performed.

07/07/16
20160195530 
 Method for analysis of nkt cell function patent thumbnailMethod for analysis of nkt cell function
The present invention provides a superior method of functional analysis of nkt cells, which enables function analysis of low frequency nkt cells, is independent of the function of autologous apcs, and can avoid an influence of secondary factors and the like. More specifically, the present invention provides a method of functional analysis of human nkt cells including (a) cocultivating a mononuclear cell derived from human peripheral blood with a cd1d-expressing antigen presenting cell derived from a heterologous animal, and (b) evaluating the functionality of nkt cells with the number of nkt cells and/or a substance specific to functional nkt cells as an index; a reagent for analysis of human nkt cells containing a cd1d-expressing antigen presenting cell derived from a heterologous animal; a kit containing (a) a cd1d-expressing antigen presenting cell derived from a heterologous animal, and (b) at least one reagent selected from the group consisting of a reagent for selection of human mononuclear cell, a reagent for measurement of the number of human nkt cells and a reagent for measurement of a substance specific to human functional nkt cells; and the like..
Riken


07/07/16
20160193386 
 Neocartilage constructs using universal cells patent thumbnailNeocartilage constructs using universal cells
The invention relates to implantable systems for repairing and restoring cartilage. The invention provides methods and products for cartilage repair that use universal chondrocytes.
Histogenics Corporation


07/07/16
20160193382 
 A flap for de-novo tissue regeneration patent thumbnailA flap for de-novo tissue regeneration
The present invention provides an implant which includes: (a) an autologous engineered tissue; and (b) a vasculature, wherein the engineered tissue is a porous scaffold embedded with endothelial cell, a fibroblast, a myoblast, a mesenchymal cell, an adipocyte, or any combination thereof, wherein the vasculature feeds the cells. Further, the invention provides a method for treating a subject afflicted with a large soft tissue defect by implanting the implant of the invention..
Health Corporation-rambam


06/30/16
20160184256 
 Method of treating disorders of the cardiovascular system and a pharmaceutical agent patent thumbnailMethod of treating disorders of the cardiovascular system and a pharmaceutical agent
Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too..

06/23/16
20160176987 
 Method of treating a pathological syndrome and a pharmaceutical agent patent thumbnailMethod of treating a pathological syndrome and a pharmaceutical agent
Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too..

06/09/16
20160158425 
 Apparatus for blood concentration patent thumbnailApparatus for blood concentration
A disposable blood transfer conduit is used in association with a pump drive unit, a blood collection vessel and a blood concentration device. The blood transfer conduit comprises a blood transfer tube (13) and a peristaltic pump element (12) having an enclosed housing mounted about the blood transfer tube (12).
Brightwake Limited


06/02/16
20160152951 
 Regulatory b cells (tbregs) and their use patent thumbnailRegulatory b cells (tbregs) and their use
Regulatory b cells (tbreg) are disclosed herein. These regulatory b cells express cd25 (cd25+) a pan b cell marker such as b220 (b220+), and also express cd19 (cd19+).
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


05/26/16
20160144018 

Methods of preparing anti-human papillomavirus antigen t cells


Disclosed are methods of preparing an isolated population of human papillomavirus (hpv)-specific t cells comprise dividing an hpv-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining t cells from the cultured multiple fragments; testing the t cells for specific autologous hpv-positive tumor recognition; selecting the t cells that exhibit specific autologous hpv-positive tumor recognition; and expanding the number of selected t cells to produce a population of hpv-specific t cells for adoptive cell therapy. Related methods of treating or preventing cancer using the t cells are also disclosed..
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


05/26/16
20160143939 

Compositions, kits and methods for treatment of cardiovascular,immunological and inflammatory diseases


Compositions, kits, cells and methods for treating cardiovascular (e.g., myocardial ischemia and heart failure), immunological, and inflammatory diseases or disorders involve the use of the mature and precursor sequences of micrornas 142-5p, 142-3p, 17-5p, 17-3p, 374, and 20a, and of antisense molecules complementary to these sequences, to manipulate processes relevant to, for example, the cardiac response to stress, including survival signaling, angiogenesis, stem cell differentiation along muscle or vascular lineages, and repression or promotion of cardiac myocyte growth. Also described are methods to treat cardiovascular, immunological and inflammatory diseases by engineering cells containing specific micro-rnas or antagomirs against specific mrnas.
University Of Miami


05/19/16
20160136327 

3d tissue-engineered bone marrow for personalized therapy and drug development


A tissue-engineered bone marrow for personalized therapy of a patient is described. The tissue-engineered bone marrow includes an autologous fibrin scaffold and a plurality of patient-derived cells isolated from the patient's bone marrow.
Washington University


05/19/16
20160136239 

Method for producing autologous proteins


A method of introducing proteins to a patient is provided for treating a wide variety of diseases. The method includes collecting blood from a patient's vein.
Arthrogen Gmbh


05/12/16
20160130557 

Formulations containing and kit for using adipose-derived stem cells and use thereof


Methods and kits for producing cellular fractions enriched in adipose derived stem cells. Methods are provided where adipose tissue obtained from liposuction is enzymatically treated using a solution containing collagenase and divalent cations prior to the application of traditional methods of stromal-vascular fraction isolation.
Antria, Inc.


05/12/16
20160129097 

Method of processing a veterinary tumor vaccine and a veterinary tumor vaccine processing kit


The present invention provides methods for preparing and administering a tumor vaccine. The processes include resecting tumors and isolating tumor cells, followed by treatment with ultraviolet radiation to activate the tumor cells.

05/05/16
20160121036 

Extemporaneous preparation of autologous fibrin


An autologous fibrin is prepared extemporaneously from either a full blood sample or a prepared sample of poor platelet plasma wherein the latter is subjected to a dedicated treatment and combined isolation process performed by a removable single-use device wherein blood or plasma components are separated and subsequently treated individually to be eventually combined by the user outside the system. The the system includes a platform and a removable single-use device both being designed to cooperate mechanically..
Avance Medical SÀrl


04/28/16
20160113779 

Harvesting bone graft material for use in spinal and other bone fusion surgeries


A technique for harvesting bone graft material for spinal and other fusion surgeries. In the disclosed embodiment, a bone cutting blade is placed in a disc space between two vertebrae to be fused.

04/21/16
20160106780 

Methods and compositions for optimized expansion and implantation of mesenchymal stem cells


Compositions and methods are provided for the optimized expansion and implantation of mesenchymal stem cells into a patient in need thereof. autologous mesenchymal stem cells (mscs) to a patient in need of mscs are harvested, expanded within novel growth parameters under the influence of autologous growth factors located on the patient's platelets..

04/21/16
20160106710 

Wound healing via autologous stem cell mobilization


The present invention relates to the field of wound healing. More specifically, the present invention provides methods and compositions useful for improved wound healing via autologous stem cell mobilization.

04/14/16
20160101217 

Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair


A rapid method for preparing stem cell and physiologically acceptable matrix compositions for use in tissue and organ repair is described. Compared with previous tissue engineering materials, the stem cell-matrix compositions of the present invention do not require long-term incubation or cultivation in vitro prior to use in in vivo applications.

04/14/16
20160101133 

Organoids comprising isolated renal cells and use thereof


Described herein are organoids comprising admixtures of selected bioactive primary renal cells and a bioactive cell population, e.g., an endothelial cell populations, e.g. Huvec cells, and methods of treating a subject in need thereof with such organoids.

04/14/16
20160101132 

Enhanced anabolic cytokine production and delivery system


Techniques and devices for removing (filtering out) unwanted/inhibitory components (for example, products, byproducts and/or cell output such as inhibitory catabolic proteins) from a composition (for example, autologous fluid or serum) containing such unwanted/inhibitory components. The devices include at least one construct designed to contain a composition (for example, autologous fluid or serum) containing inhibitory/unwanted components (products, byproducts and/or output of cells such as inhibitory catabolic proteins).

03/24/16
20160082113 

Altering a b cell pathology using self-derived antigens in conjunction with specific-binding cytoreductive agent


A method of treating b cell malignancies or a method for preparing compositions for treating b cell malignancies wherein administration of a specific binding cytoreductive agent is followed by immunization with an autologous id protein. The two treatments may be sequential, where the administration of the specific binding cytoreductive agent is completed before the administration of the autologous id protein, or the administration of the specific binding cytoreductive agent and the immunization with an autologous id protein may occur in an overlapping time course..
Mmrglobal, Inc.


03/17/16
20160074479 

Methods of treating spinal disorders using autologous protein solutions


Methods for treating a spinal disorder, such as spinal pain or spinal inflammation, using a blood-derived composition having two or more of il1-ra, stnf-r1, stnf-rii, igf-i, egf, hgf, pdgf-ab, pdgf-bb, vegf, tgf-β1, and sil-1rii. Compositions may also contain white blood cells and platelets..

03/10/16
20160067674 

Ligands and methods for isolating or removing proteins


The present disclosure relates generally to sorbents for binding proteins from blood plasma comprising a solid carrier material and an oligopeptide immobilized thereon, which selectively binds the protein from the blood plasma, and to a method for separating autologous proteins from blood plasma wherein the blood plasma is brought in contact with a corresponding sorbent, the desired protein is allowed to bind to the sorbent, the sorbent is separated from the plasma and the protein is subsequently separated from the sorbent. Corresponding sorbents and method allows for the selective isolation of specific blood plasma proteins directly from the blood plasma without having to conduct a tedious fractionation.
Previpharma Ag


03/10/16
20160066563 

Compositions and methods for collecting, washing, cryopreserving, recovering and return of lipoaspirates to physician for autologous adipose transfer procedures


The invention details a cryoprotectant and the methods to prepare biological tissue and related business methods and systems. The invention is directed to methods for collecting, washing, cyropreserving, recovering, and return of lipoaspirates to physicians for autologous adipose tissue transfer procedures in patients.

03/03/16
20160058855 

High purity ovarian cancer stem cells for active autologous immune therapy


The disclosure provides cancer stem cells, for use in stimulating immune response against a cancer, such as ovarian carcinoma. Methods for preparing and purifying the cancer stem cells are provided..
Neostem Oncology, Llc


03/03/16
20160058798 

Method of treating pancreatic and liver conditions by endoscopic-mediated (or laparoscopic-mediated) transplantation of stem cells into/onto bile duct walls of particular regions of the biliary tree


A method of repairing diseased or dysfunctional pancreas or liver is provided. The method involves preparation of a suspension of stem cells and/or progenitor cells such as biliary tree stem cells, hepatic stem cells, pancreatic stem cells or their descendants, committed progenitor cells, from healthy tissue of the patient or of the biliary tree of a non-autologous donor and engrafting the cells into the wall of bile ducts near to the organ to be treated.
University Of Miami


02/25/16
20160051729 

Reparative cell isolation and delviery


Methods are described for generating autologous tissue grafts, including generating grafts at the point of care, which include isolated cell populations that are enriched with stem cells and are mixed with biological fillers including hyaluronic acid and derivatives thereof. The hyaluronic acid localizes the cells to a desired injection site and stimulates collagen production thus enhancing the viability and the longevity of the graft..
Board Of Regents, The University Of Texas System


02/25/16
20160051653 

Tumor vaccination in combination with hematopoietic cell transplantation for cancer therapy


In one aspect, the present invention provides a method for treating cancer comprising tumor cell vaccination in combination with hematopoietic and immune cell transplantation. In some embodiments, the method involves autologous tumor cell vaccination prior to autologous hematopoietic and immune cell transplantation.
The Board Of Trustees Of The Leland Stanford Junior University


02/25/16
20160051588 

Method of using stem cells and nanowhiskers


The present invention relates to methods of improving stem cell delivery to a subject in need thereof and kits designed to assist in such. The methods comprise interchangeably allowing or promoting cell growth in conditions that permit three-dimensional growth, such as with a bioreactor and/or through the introduction of nanofibers to cells in suspension, utilizing allogeneic cells that are mixed with platelet rich plasma that is autologous to the subject, and site specific delivery of between 5 and 15 million stem cells at the site or of about 3-10 million stem cells per kilogram of the subject receiving the treatment..

02/25/16
20160051586 

Methods of growing and preparing stem cells and methods of using the same


The present invention relates to methods of improving stem cell delivery to a subject in need thereof and kits designed to assist in such. The methods comprise interchangeably allowing or promoting cell growth in conditions that permit three-dimensional growth, such as with a bioreactor, utilizing allogeneic, autologous or xenogeneic cells, mixing the cells with platelet rich plasma that is autologous, allogeneic or xenogeneic to the subject, and site specific delivery of between about three and ten million activated stem cells per kilogram of the subject receiving the treatment..

02/25/16
20160051530 

Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies


Methods of treating, preventing and/or managing multiple myeloma are disclosed. Specific methods encompass the administration of an immunomodulatory compound, e.g., lenalidomide or pomalidomide with an anti-cs1 antibody, e.g., elotuzumab in patients who have received autologous stem cell transplantation..
Celgene Corporation


02/25/16
20160051333 

Method and system for preparing soft tissue for grafting, enhancing grafting results, and grafting autologous fat and adipocyte derived stem cells to soft tissue such as the breast and other tissue defects


A method is disclosed for preparing a soft tissue site, and augmenting the soft tissue site, such as the breast(s), scar, depression, or other defect, of a subject through use of devices that exert a distractive force on the breast(s) and grafting of autologous fat tissue such as domes with sealing rims for surrounding each of the soft tissue site and a regulated pump. The method for preparing the soft tissue site, and enhancing fat graft results, entails application of the distracting force to the targeted soft tissue site at least intermittently for some period of time and preferably several weeks prior to the graft procedure.

02/11/16
20160038656 

Intra-operative blood recovery system


A method for recovering blood from a blood-laden surgical sponge for autologous reinfusion, the method comprising the steps of: conveying negative pressure to a housing with the blood-laden surgical sponge; applying a predetermined force to draw the blood from the surgical sponge; and collecting the recovered blood.. .
Procell Surgical Inc.


02/04/16
20160032322 

Microvesicles


A method of producing a population of differentiated cells comprising: a) inducing differentiation in a first population of cells by applying an inducer to said cells, b) harvesting microvesicles produced from first population of cells, and c) inducing differentiation in a second population of cells by applying said microvesicles or a derivative thereof to said second population of cells wherein, said first population of cells is autologous to said second population of cells and wherein the inducer applied to said first population of cells is not present in said second population of cells or is only present in trace amounts. Also related methods of producing microvesicles, methods of medical and/or cosmetic treatment and related products and uses..
Lydac Neuroscience Limited


01/28/16
20160024469 

Non-conventional cellular based immunotherapy


Most importantly non-obviousness of this patent is clearly elucidated in the proposed method of immunotherapy whereby cancer stem cells (either directly isolated in culture or created by an induced process like ipscs) are lysed for their protein antigens and electroporated or incubated with novel immunogenic cells (not dendritic cells) such as svf and given back to the same patient in an autologous and personalized fashion. (in this way both mhc i and mhc ii pathways may be utilized and a plurality of non-dendritic cells with antigen presenting capabilities are advantageously used in a plural immune like fashion raising immunogenicity through multiple novel and unique epitopes..

01/28/16
20160024167 

Methods and compositions based on diphtheria toxin-interleukin-3 conjugates


The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (dt-il3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the dt-il3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3.
Scott & White Memorial Hospital


01/21/16
20160015721 

Compositions and methods for cartilage repair


autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies..
Regenerative Sciences, Llc


01/14/16
20160011177 

Screening therapeutic agents for charcot-marie-tooth disease and self-differentiation motor neurons used therefor


The present invention relates to a method for the screening of a therapeutic agent for charcot-marie-tooth disease (cmt) using induced pluripotent stem cells and motor neurons differentiated therefrom. Particularly, the present inventors prepared induced pluripotent stem cells from the human fibroblasts originated from cmt patient.
Samsung Life Public Welfare Foundation


01/14/16
20160008446 

Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer


The present disclosure provides compositions comprising mature dendritic cells loaded with autologous tumor cell lysates for the treatment of liver cancers, such as hepatocellular carcinoma. Hepatocellular carcinoma (hcc) is the fifth leading cancer and third leading cause of cancer-related mortality worldwide.
Icahn School Of Medicine At Mount Sinai


01/07/16
20160003856 

Skin model


A three dimensional (3-d) model comprising a scaffold and autologous skin cells, the invention also provides methods of predicting immunogenicity and hypersensitivity or allergic or adverse immune reactions to potential therapeutic compounds, biologies, cosmetics and chemical sensitizers using the 3-d model of skin cells. The methods provide an in vitro assay employing autologous blood derived cells in the 3-d skin equivalent model and is of particular utility in the identification and prediction of skin sensitizers and in particular agents that may cause allergic contact dermatitis.
Alcyomics Ltd


01/07/16
20160002598 

Device and methods for platelet lysis or activation


Device, system and method embodiments are disclosed herein which provide for the production of a modified autologous platelet solution at the patient bedside for contemporaneous reinjection to the patient. In certain embodiments all of the steps including, but not limited to blood draw, platelet lysis, solution preparation and reinjection to a patient may be accomplished in a single office or clinic visit without relocating the patient.
Regenerative Science, Llc


01/07/16
20160000829 

Methods for treating chronic lymphocytic leukemia (cll)


The present invention relates generally to the treatment of pml by infusion of activated and expanded autologous lymphocytes.. .
The Trustees Of The University Of Pennsylvania


01/07/16
20160000063 

Composition and preserving, transporting and storing living biological materials


Compositions and methods for preserving, transporting and/or storing natural and bioengineered living biological materials represent significant improvements over traditional compositions and methods for preservation, transport and/or storage of biological material by the virtue of their ability to significantly prevent and minimize loss of functional and physical (cell, tissue, and/or organ) integrity to occur in the biological material being preserved, transported and/or stored, particularly at temperatures above freezing point. The compositions and methods are also highly suitable for use in cosmetic procedures, in particular in transplantation of biological materials, especially for transplantation of autologous or allogeneic biological materials..

12/31/15
20150376573 

Autologous and allogenic adipose-derived stromal stem cell composition for treating fistulas


The present invention relates to a method for producing clinically effective quantities of human adipose tissue-derived stromal cells for treating fistulas and a composition made with the same. The method of the present invention can efficiently produce clinically effective number of adipose tissue-derived stromal cells within a short period by improving conventional standard culturing methods.
Anterogen Co., Ltd.


12/31/15
20150376564 

Systems and methods for autologous biological therapeutics


An autologous cell concentrating system and method are disclosed. The system has a blood separation component, a first vessel, a second vessel, a first valve, a second valve, and a concentration and flow logic and control component.
Greyledge Technologies Llc


12/31/15
20150374581 

Use of autologous serum for transport of isolated stromal vascular fraction or adipose derived stem cells for reinjection


This invention is directed to devices and methods for use of an autologous serum for transport of isolated stromal vascular fraction or adipose derived stem cells for reinjection.. .

12/17/15
20150361390 

Composition and generating a desired cell type and/or tissue type from hair follicular stem cells


The present invention is concerned with a composition and in vitro method for generating a desired cell type and/or tissue type from hair follicular stem cells. The composition and in vitro method are particularly suitable for generating an autologous desired cell type and/or tissue type.

12/17/15
20150359630 

Systems and methods for endoluminal valve creation


Medical systems, devices and methods for creation of autologous tissue valves within a mammalian body are disclosed. One example of a device for creating a valve flap from a vessel wall includes an elongate tubular structure having a proximal portion and a distal portion and a longitudinal axis; a first lumen having a first exit port located on the distal portion of the elongate tubular structure; a second lumen having a second exit port located on the distal portion of the elongate tubular structure; a recessed distal surface on the distal portion of the elongate tubular structure, wherein the recessed distal surface is located distally to the first exit port; and an open trough on the recessed distal surface extending longitudinally from the first exit port..
Intervene, Inc.


12/10/15
20150353887 

Compositions and methods for autologous germline mitochondrial energy transfer


Oogonial stem cell (osc)-derived compositions, such as nuclear free cytoplasm or isolated mitochondria, and uses of osc-derived compositions in autologous fertility-enhancing procedures are described.. .
The General Hospital Corporation


12/10/15
20150352263 

Medical device with coating that promotes endothelial cell adherence


The invention relates to a method for healing blood vessels by stimulating the formation of a confluent endothelial autologous cell layer in vivo on an implantable metallic stent having a lumen and a luminal surface, and an exterior surface. More specifically, the method includes implanting the stent with a coating in a patient in need of thereof; wherein the coating includes one or more layers of a matrix covalently adherent on said luminal and exterior surface of said stent containing one or more pharmaceutical substances on said exterior surface and a therapeutically effective amount of a single type of antibody, antibody fragments or combinations thereof being compatible to binding selectively to a specific cell surface antigen of circulating autologous endothelial progenitor cells in peripheral blood.
Orbusneich Medical Inc.


12/10/15
20150352261 

Medical device with coating that promotes endothelial cell adherence


The invention relates to a method for healing blood vessels by stimulating the formation of a confluent endothelial autologous cell layer in vivo on an implantable metallic stent having a lumen and a luminal surface, and an exterior surface. More specifically, the method includes implanting the stent with a coating in a patient in need of thereof; wherein the coating includes one or more layers of a matrix covalently adherent on said luminal and exterior surface of said stent containing one or more pharmaceutical substances on said exterior surface and a therapeutically effective amount of a single type of antibody, antibody fragments or combinations thereof being compatible to binding selectively to a specific cell surface antigen of circulating autologous endothelial progenitor cells in peripheral blood.
Orbusneich Medical Inc.


12/10/15
20150352255 

Preparation of extracellular matrix-modified tissue engineered nerve grafts for peripheral nerve injury repair


A tissue engineered nerve graft for repairing peripheral nerve injury consists of a nerve conduit and a extracellular matrix (ecm) that is secreted by autologous or allogeneic support cells and obtained by decellularization. A preparation method of the ecm-modified tissue engineered nerve grafts containing support cells, nerve conduit and constructing a ecm-modified tissue engineered nerve graft..
Nantong University


12/03/15
20150344844 

Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof


Provided herein are methods for manufacturing t cells. In certain embodiments, methods for manufacturing t cells which express a cell surface receptor that recognizes a specific antigenic moiety on the surface of a target cell are provided.

12/03/15
20150343040 

Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy


The present invention relates to the treatment and prevention of cancer. The present invention relates to vaccines comprising solubilized components of cancer cells or cancer-associated cells.
Northern Sydney Local Health District


12/03/15
20150342828 

Method for the filling of containers with autologous fresh blood components


D) insulating the first gap (3a) from the third gap (3c) and placing in communication the latter with the second gap (3b), the containers suctioning the contents of the bag (5) due to the effect of the vacuum defined inside them.. .

12/03/15
20150342631 

Systems and methods for endoluminal valve creation


Systems and methods for creating autologous monocuspid and bicuspid valves can include a catheter having a single expandable element or a double expandable element. Once the leaflets of the valve are created, various techniques can be used to fix the leaflets to the vessel wall or to each other, including clips, tissue anchors, adhesives, and heat..
Intervene, Inc.


11/26/15
20150335422 

Pericardial heart valve replacement and methods of constructing the same


The pericardial heart valve replacement (1) is constructed from living tissue of autologous pericardium containing living pericardial interstitial cells (pics) and a living extracellular matrix (ecm) in the following way: in the first step the size and shape of the patient's native pathological heart valve is determined using real-time three-dimensional transesophageal echocardiography (tee) or computer tomography (ct angiography) or magnetic resonance imaging (mri); in the next step a stented (2) or a stentless pericardial heart valve replacement (1) is constructed from a single sheet of living autologous pericardium obtained from the patient; the size and shape of the pericardial heart valve replacement (1) corresponds to the size and shape of the patient's native heart valve and aortic or pulmonary root. The subject matter of the invention also includes the development of a device (5) for the conditioning and modification of the living autologous pericardial heart valve replacement (1) consisting of a ipulsatile pump (6) driving the flow of culture medium in the device (5) to perfuse the cells in the pericardium, a reservoir (7) regulating the fluid capacitance and function of the pericardial heart valve replacement (1), a chamber (8) containing a holder (9) for the placement of the pericardial heart valve replacement (1) during dynamic conditioning, and a gas exchanger (10a, b) for perfusing c02 into the culture medium.
Institut KlinikÉ A ExperimentÁlnÍ MedicÍny


11/19/15
20150329873 

Furin-knockdown and gm-csf-augmented (fang) cancer vaccine


Compositions and methods for cancer treatment are disclosed herein. More specifically the present invention describes an autologous cancer vaccine genetically modified for furin knockdown and gm-csf expression.
Gradalis, Inc.


11/12/15
20150323547 

Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration


A method for diagnosing or treating a mammalian subject having, or at risk of developing cancer, comprising: generating a circulating anti-cancer cd4+ th1 response from antigen presenting cells or their precursors and cd4+ t-cells from a sample of said subject's blood which causes secretion of interferon-gamma (“ifn-γ”); and detecting said anti-cancer cd4+ th1 response to determine if said response is depressed. A method for restoring her2-specific cd4+ th1 immune response in a her2-positive breast cancer patient in need thereof, comprising: administering to said patient a therapeutically effective amount of a dendritic cell (“dc”) vaccine comprising autologous dcs pulsed with her2-derived mhc class ii binding peptides (“dc vaccination”) to elevate said patient's anti-her2 cd4+ th1 response; and measuring said anti-her2 th1 response of said patient pre- and post-dc vaccination to determine the amount of increase in said response..

11/12/15
20150320447 

Lamina implant and method


A prosthetic implant for restoring lamina after a laminectomy. The implant is generally a lamina-sized construct having a hollow interior.
Globus Medical, Inc.


10/22/15
20150299800 

Monitoring mantle cell lymphoma clonotypes in peripheral blood after immunotransplant


The invention is directed to a method of monitoring a mantle cell lymphoma residual disease in an immunotransplant patient by post-treatment analysis of clonotype profiles from patient blood samples. In some embodiments, methods of the invention comprising steps of (a) treating a patient by immunotransplanting the patient with vaccine-primed autologous t cells; (b) obtaining a peripheral blood sample from the patient comprising b-cells and/or cell-free nucleic acids; (c) amplifying molecules of nucleic acid from the b-cells of the sample and/or cell-free nucleic acids in the sample, the molecules of nucleic acid comprising recombined dna sequences from immunoglobulin genes; (d) sequencing the amplified molecules of nucleic acid to form a clonotype profile; and (e) determining from the clonotype profile a presence, absence and/or level of the one or more patient-specific clonotypes correlated with the mantle cell lymphoma, including phylogenic clonotypes thereof..
Sequenta, Inc.


10/15/15
20150290360 

Method of preparing an implantable neuroendoprosthetic system


A method of making an implantable neuroendoprosthetic system for transubstantiation of defects of brain, spinal cord and vegetative nervous system in a mammal in reconstructive neurosurgical operations provides a heterogeneous collagen-containing matrix for implantation, a cell preparation of autologous cells of a patient, and the cell preparation is perfused into said matrix to make an elastic cell-biopolymer biologically active mass. The cell preparation comprises placed in a nacl solution at least one type of cells from a group comprising neural stem cells (nsc), neuroglial ensheathing cells (ngec), endothelial cells with cd34+ marker (ec), and purified mononuclears (mn).

10/08/15
20150284701 

Fusion proteins of collagen-binding domain and parathyroid hormone


Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (pth) and parathyroid hormone related peptide (pthrp) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy.

09/24/15
20150265263 

Visualization devices for use during percutaneous tissue dissection and associated systems and methods


A device and method for visualization of the intravascular creation of autologous valves, and particularly venous valve, is disclosed herein. One aspect of the present technology, for example, is directed toward a delivery catheter that can include a lumen configured to receive a dissection assembly and a trough having a plurality of transducers electrically coupled to a proximal portion of the delivery catheter.
Intervene, Inc.


09/17/15
20150259749 

Methods for producing high-fidelity autologous idiotype vaccines


The present invention concerns methods for selecting and producing idiotype vaccines, and in particular methods for selecting and producing an idiotype vaccine for treatment of a b-cell derived malignancy in a subject based on the clonal profile (clonotype) of the malignancy; a method for producing an updated idiotype vaccine matched to a b-cell derived malignancy exhibiting a shifting clonal profile; and the high-fidelity idiotype vaccines produced using the methods. The invention also includes idiotype vaccines produced using the described methods and methods of treating b-cell derived malignancies using the produced vaccines..
Biovest International, Inc.


09/17/15
20150259649 

Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto


This disclosure relates to compounds, compositions and methods of epigenetically transforming cells. In certain embodiments, the disclosure relates to methods of generating epigenetically altered cells comprising mixing isolated cells with compositions disclosed herein under conditions such that epigenetically altered cells are formed.
Emory University


09/17/15
20150259646 

Methods for isolating and proliferating autologous cancer antigen-specific cd8+ t cells


Provided is a method for isolating and proliferating autologous cancer antigen-specific cd8+t cells, and more particularly, a method for selecting an epitope recognized by cd8+ t cells from autologous cancer antigens present in blood of individual cancer patients; and isolating autologous cancer antigen-specific cd8+ t cells by using a peptide of the selected epitope, and a method of massively proliferating cd8+ t cells by using the method. According to the present invention, it is possible to isolate autologous cancer antigen-specific cd8+ t cells by using the peptide of the cd8 t cell epitope of the autologous cancer antigen present in blood of individual cancer patients instead of a heterologous antigen.
National Cancer Center


09/17/15
20150258145 

Tissue transplant compositions and methods for use


Provided are transplants and methods for augmenting formation and restoration of organ and tissue, for example, bone formation, by administering autologous or allogeneic human embryonic-like adult stem cells (ela cells). Also provided is a method for augmenting formation of tissues and organs by administering a transplant having ela stem cells or combination of ela stem cells..
Parcell Laboratories Llc


08/06/15
20150216935 

Autologous cell-based therapy for treating obesity


Compositions and methods for producing autologous brown adipose cells in vitro or in vivo are provided. In particular, a drug delivery device is described that recruits adipose stem cells (ascs) to a site in the body of a subject.
Brown University


07/30/15
20150209476 

Method for manufacturing allogeneic soft-tissue transplant having autologous stem cell transplanted therein


Provided is a method of manufacturing an allogeneic soft-tissue transplant having autologous stem cells transplanted therein using an allogeneic soft-tissue support that is obtained from an allogeneic organism. In this regard, an allogeneic soft-tissue transplant that can replace a damaged soft-tissue of a human body is manufactured..
Cellumed Co., Ltd.


07/23/15
20150202027 

Method for digital archiving and manufacturing of dental prosthetics and prosthesis, and teaching and training for same


A method for digital archiving and manufacturing of dental prosthetics and a prosthesis, and teaching and training for same are provided. The method mainly includes the following steps: preoperative scanning: creating a first digital model file; optical positioning and turning treatment: creating a second digital model file from a turning process; physical model calculation: creating reversely an autologous crown model file of a patient; and fixed denture manufacturing: manufacturing, according to the second digital model file and the autologous crown model file, a fixed denture that meets needs of the patient, so that an inner layer structure of a crown of the fixed denture can be tightly bound to an abutment, and it may be decided to retain an original crown contour according to needs.
Eped Inc.


07/23/15
20150201588 

Autologous mammalian models derived from induced pluripotent stem cells and related methods


Disclosed is an autologous non-human mammalian model system derived from induced pluripotent stem (ips) cells. Also disclosed are methods of differentiating non-human primate ips cells, which can result in populations of cells enriched for sox2+ or pdx1+ foregut-like cells, for cdx2+ hindgut-like cells, for cd34+ hematopoietic progenitor-like cells, or epithelial-like cells.
Amgen Inc.


07/02/15
20150183793 

Compounds and methods for kinase modulation, and indications therefor


Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on one or more of fms, kit, flt3, trka, trkb and trkc kinase protein.
Plexxikon Inc.


06/25/15
20150174221 

Systems, compositions, and methods for transplantation


Systems and methods for purification and concentration of autologous alpha-2-macroglobulin (a2m) from whole blood are provided. Also provided are diagnostic methods for identifying sites in the synovial joints, spine, tendons or ligaments for treatment of pain, degeneration, or inflammation with autologous a2m.
Cytonics Corporation


06/18/15
20150166547 

Compounds and methods for kinase modulation, and indications therefor


Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one of fms protein kinase or kit protein kinase.
Plexxikon Inc.


06/18/15
20150164786 

Treatment for chronic myocardial infarct


A method of treating chronic post-myocardial infarction including helical needle transendocardial delivery of autologous bone marrow (abm) mononuclear cells around regions of hypo or akinesia in chronic post-myocardial infarction (mi) patients. The treatment is safe and improves ejection fraction (ef)..
Biocardia, Inc.


06/18/15
20150164486 

Method and restoring articular cartilage


The present invention comprises the provision and use of new and improved arthroscopic instrumentation for (i) harvesting a tissue biopsy from a non-critical section of a joint, and (ii) sizing and seating an autologous graft at an implant site.. .
Prochon Biotech Ltd.


06/11/15
20150157781 

Fluid concentrator, autologous concentrated body fluids, and uses thereof


The present invention provides devices and methods for concentrating a fluid and for treating a patient with the concentrated fluid. The concentrator apparatus includes a main housing (12) defining a separation chamber (14), a filter housing (48) containing a filter (46) comprising a filter element, a piping (44) for moving concentrated fluid from the separation chamber to the filter, and ports (32) for pressurizing the concentrated fluid past the filter element of the filter.
Circle Biologics, Llc


05/28/15
20150148912 

Improved absorbable patch, in reinforced pga, for the replacement of a portion of bladder wall following partial cystectomy


A patch (1) for the replacement of a portion of bladder wall, following partial cystectomy, comprises a textile (2) derived from a pga yarn and provided with a star-shaped support frame, flexible and harmonic, formed by a plurality of radial strips (3) manufactured by injection of a pga/pla copolymer, the patch (1) being suitable for making autologous fibrous capsule cells, generated by the process of tissue reconstruction, grow thereon after its insertion inside the patient.. .

05/28/15
20150148901 

Apparatus and breast reconstruction and augmentation using an autologous platelet-rich fibrin matrix


Described herein are systems and methods for soft tissue reconstruction and augmentation using a platelet-rich fibrin matrix. In one embodiment the system of the present invention includes a blood collection apparatus capable of drawing blood from a patient, a matrix preparation container configured to hold a patient's blood while the blood is separated and coagulated to form a platelet-rich fibrin matrix therein, and a matrix delivery device configured to receive the matrix preparation container therein and compress and force the platelet-rich fibrin matrix out of the matrix preparation container and into the patient.

05/21/15
20150140035 

Autologous biological cancer vaccine


The present disclosure relates to an autologous biological cancer vaccine and to a method for preparing the same. The vaccine of the present application is a biological vaccine obtained from overexpressed proteins in the serum of cancer patients, proteins to which have been added immunological adjuvants such as an attenuated virus dna and amino acids in order to cause an immune response, blocking tumor cells.
Universidad Manuela Beltran


05/14/15
20150132267 

Fibroblast mixtures and methods of making and using the same


The present disclosure provides a non-autologous product that is a mixture of two or more cells or tissue cultures of fibroblast, or extracts from cultures, or media cultures, isolated from separate individuals, either homogeneous or heterogeneous. The cells or factors are blended together in a product that imparts desired characteristics to the skin of a recipient who is not a source of the mixture.

04/30/15
20150118199 

Methods of measuring potential for therapeutic potency and defining dosages for autologous cell therapies


autologous bone marrow cells (bmc) are transplanted to a heterologous site in a patient after a sample of the patient's bmc has been tested and found to have a phenotypic profile which meets minimum criteria for transplantation. The phenotypic profile may be obtained by screening a sample of bone marrow cells (bmc) from the patient for the phenotypic profile, such as a cd profile, the phenotype profile may be assessed to determine the likelihood that the bmc will be suitable for transplantation to the heterologous tissue site without enriching particular phenotypic population(s) of the bmc..
Biocardia, Inc.


04/30/15
20150118198 

Bone marrow-derived mesenchymal stem cells as a source of neural progenitors


Methods are provided for treating and/or reducing the severity of multiple sclerosis in a human, by administering autologous mesenchymal stem cell-derived neural precursors. Also described is an in vitro method for differentiating mesenchymal stem-cell derived neural precursor oligodengroglial and neuronal cell types..
Multiple Sclerosis Research Center Of New York


04/23/15
20150110751 

Stem cells as an individualized maternal therapy for prevention of prematurity


The present invention relates to the field of premature birth. More specifically, the present invention provides methods and compositions useful for preventing premature birth.
Kennedy Krieger Institute, Inc.


04/23/15
20150110750 

Methods for using autologous fibroblasts to alter skin identity


The present invention relates to the field of autologous fibroblasts. More specifically, the present invention provides methods and compositions comprising autologous fibroblasts and uses thereof to alter skin identity.
The Government Of The United States Of America, As Represented By The Secretary Of The Army


04/09/15
20150098924 

Method for ex-vivo purging in autologous transplantation


The present invention concerns a new method for ex-vivo purging of cells in autologous transplantation, wherein the sample of taken cells is treated with a sufficient amount of a multimeric form of the soluble portion of fasl to kill malignant cells without substantially affecting viability of cells to be transplanted. Autologous stem cell transplantation (asct) following high-dose chemotherapy with or without radiotherapy has become the standard therapy for the majority of patients with large-cell lymphomas, multiple myeloma, and refractory/recidivating hodgkin's disease.
Topotarget Switzerland Sa


04/02/15
20150094532 

Visualization devices, systems, and methods for informing intravascular procedures on blood vessel valves


The present technology relates generally to devices and methods for intravascular evaluation of blood vessels. Many embodiments of the technology relate to the intravascular evaluation of blood vessels before, during and after creation of autologous valves.
Intervene, Inc.




Autologous topics: Autologous, Stem Cells, Differentiation, Fibroblast, Cell Therapy, Transplant, Cell Differentiation, Tissue Engineering, Myeloid Leukemia, Gene Expression, Acute Myeloid Leukemia, Complication, Umbilical Cord, Premature Birth, Premature Infant

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Autologous for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autologous with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.4192

4701

2 - 1 - 101